AU625379B2 - Antiplaque antibacterial oral composition - Google Patents

Antiplaque antibacterial oral composition Download PDF

Info

Publication number
AU625379B2
AU625379B2 AU46769/89A AU4676989A AU625379B2 AU 625379 B2 AU625379 B2 AU 625379B2 AU 46769/89 A AU46769/89 A AU 46769/89A AU 4676989 A AU4676989 A AU 4676989A AU 625379 B2 AU625379 B2 AU 625379B2
Authority
AU
Australia
Prior art keywords
oral composition
agent
weight
oral
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU46769/89A
Other versions
AU4676989A (en
Inventor
John Afflitto
Abdul Gaffar
Nuran Nabi
Michael Prencipe
Orum Stringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/291,712 external-priority patent/US4894220A/en
Priority claimed from US07/398,566 external-priority patent/US5032386A/en
Priority claimed from US07/398,592 external-priority patent/US5188821A/en
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of AU4676989A publication Critical patent/AU4676989A/en
Application granted granted Critical
Publication of AU625379B2 publication Critical patent/AU625379B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8164Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87Application Devices; Containers; Packaging

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Description

B
COMMONWEALTH OF AUSTRALIA Patents Act 1952 COMPLETE SP EC I FIC A TIO N C 0 M P L E T E
(ORIGINAL)
Class Int. Class Application Number Lodged Complete Specification Lodged Ac cc p ted ~?i5379 U Priority Related Art Name of Applicant Published 29 December 1.988; 25 August 1989; 25 August 1989; 25 August 1989; August 1989; 25 August 1939; .21 September 1989 COLGATE-PALMOLIVE COMPANY2 Address of Applicant Actual Inventcar(s) Address for Service *00Complete Specif icationi for the 300 Park Avenue New York, N.Y. 10022 United States of America -Nuran Nabi; Abdul Gaffar John Afflitto; Orum Stringer; Michael Prencipe RICE CO., PatenL Attorneys 28A Monta~gue Street I3ALMAIN NSW 2041 invention entitled: ANTIPLAQUE ANTIBACTERIAL ORAL COMPOSITION The following statement is a full description of this invention including the best method of performing it known to us 0~ o 0.
0 0 0~~44* 0 04 *4 0 S 0 0 04*400 0 '4) r
I
In an aspect of the Invention, the oral V I This invention relates to an antibacterial antiplaque oral composition dentifrice. More particularly, it relates to an oral composition dentifrice containing a substantially water-insoluble noncationic antibacterial agent effective to inhibit plaque.
Dental plaque is a soft deposit which forms on teeth as opposed to calculus which is a hard calcified deposit on teeth. Unlike calculus, plaque may form on any part of the tooth surface, particularly including at the gingival I0 margin. Hence, beside being unsightly, it is implicated in the occurence of gingivitis.
Accordingly, it is highly desirable to include antimicrobial agents which have been known to reduce plaque in oral compositions. Frequently, cationic antibacterial agents have been suggested. Moreover, in U.S. Patent 4,022,880 to Vinson et al, a compound providing zinc ions as an anticalculus agent is admixed with an antibacterial agent effective to retard the growth of plaque bacteria. A wide variety of antibacterial agents are described with the zinc °O compounds including cationic materials such as guanides and E quaternary ammonium coumpounds as well as non-cationic 0 e compounds; such as halogenated salicylanilides and 0 o0 halogenated hydroxydiphenyl ethers. The noncationic antibacterial antiplaque halogenated hydroxydiphenyl ether, o 44 triclosan, has also been described in combination with zinc ~citrate trihydrate in European Patent Publication 0161,899 to Saxton et al. Triclosan is also disclosed in European Patent Publication 0271,332 to Davis as a toothpaste component conteining a solubilizing agent such as propylene 3 glycol. The cationic antibacterial materials such as chlorhexidine, benzthonium uhlloride and cetyl pyridinium chloride have been the subject of greatest investigation as 2 1i r i h antibacterial antiplaque agents. However, they are generally not effective when used with anionic materials.
Noncationic antibacterial materials, on the other hand, can be compatible with anionic components in an oral conposition.
However, oral compositions typically are mixtures of numerous components and even such typically neutral materials as humectants can affect performance of such compositions.
Moreover, even noncationic antibacterial agents may have limited antiplaque effectiveness with commonly used materials such as polyphosphate anticalculus agents which are disclosed together in British Patent Publication 22 00551 of Gaffar et al and in EP 0251591 of Jackson et al.
In commonly assigned U.S.S.N. 398,605, filed on August 1989, it is shown that the antiplaque effectiveness is greatly enhanced by including an antibacterial-enhancing agent (AEA) which enhances the delivery of said antibacterial agent to, and retention thereof on, oral S surfaces and providing optimized amounts and ratio of polyphosphate and AEA.
o a It is an advantage of this invention that an oral composition is provided wherein a substantially waterinsoluble noncationic antibacterial agent and :n AEA is provided to inhibit plaque formation, wherein the oral O.o us composition contains an orally acceptable liquid vehicle effective to enable said antibacterial agent to dissolve in saliva in effective antiplaque amount.
It is a further advantage of this invention that the 3 AEA enhances the delivery and retention of small but as effective antiplaque amount of the antibacterial agent on teeth and on soft oral tissues.
4 It is a further advantage of this invention that an 3 L C
I
1 antiplaque oral composition is provided which is effective to reduce the occurence of gingivitis.
Additional advantages of this invention will be apparent from consideration of the followig' specification.
In accordance with certain of its aspects, this invention relates to an oral comnosition comprising an effective antiplaque amount of a substantially water insoluble noncationic antibacterial agent, about 0.005-4% by weight of an antibacerial-enhancing agent which enhances C0 the delivery of said antibacterial agent to, and retention thereon, oral surfaces and an orally acceptable vehicle effective to enable said antibacterial agent to dissolve in saliva in effective antiplaque amount, said oral composition being substantially free of polyphosphate anticalculus agent.
Typical examples of water insoluble noncationic antibacterial agents which are particularly desirable from considerations of antiplaque effectiveness, safety and formulation are: )O Halogenated Diphenyl Ethers 2, 2',4,4'-trichloro-2-hydroxy-diphenyl ether (Triclosan) a 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether.
V. Halogenated Salicylanilides or e 3,4',5-trichlorosa.cylanilide 3,4',5-tribromosalicylanilide 2,3,3' 3,3,3',5-tetrachlorosalicylanilide 3,5-dibromo-3'-trifluoromethyl salicylanilide 5-n-octanoyl-3'-trifluoromethyl salicylanilide 3,5-dibromo-4'-trifluoromethyl salicylanilide a" 3,5-dibromo-3'-trifluoro methyl salicylanilide (Flurophene) 4 o*
B
Oc.i 9 i Benzoic Esters Methyl p-Hydroxybenzoic Ester Ethyl p-Hydroxybenzoic Ester Propyl p-Hydroxybenzoic Ester Butyl p-Hydroxybenzoic Ester Halogenated Carbanilides 3, 4,4' -trichlorocarbanilide 3-trifluoromethyl-4, 4'-dichlorocarbanilide 3,3, 4'-trichlorocarbanilide Phenolic Compounds (including phenol and its homologs, mono- and poly-alkyl and aromatic halo F, Cl, Br, phenols, resorcinol and catechol and their derivatives and bisphenolic compounds) Phenol and its Homologs Phenol 2 Methyl Phenol 3 Methyl Phenol 4 Methyl Phenol o 0:.4 Ethyl Phenol o ,-imty -Peo 2,4-Dimethyl Phenol @000mthl heo Phenol 034-Dimtyl Phenol 2,6-Dietyl Phenol 04 4-n-Butyl Phenol 04
I
0 2-Metlhoxy-4- (2-Propenyl) -Phenol (Eugenol) Phenol (Thymol) Mono- and Poly-Alkyl and Aralkyl Halophenols Methyl -p-Chlorophenol 00 0~ 0 o
O~
0 0 0 0 099 0 00 o~3 09 0 0 0 0 09 0 Ethyl n-Pr opyl n-ButyJ.
n-Amy].
sec -Amy].
n-Hexyl cyclohexyl n-Heptyl n-Octyl IC 0-Chiorophenol Methyl Ethyl n-Propyl n-Butyl n-Amy.
tert-Amy.
n-Hexy.
n-Hoptyl p-Ch].oiophono.
O-Bezy, o-Benzy..-m-methy.
o-Benzy.-m, m-dimethy.
o-Pheny.ethy.
o-Pheny.cthyl-m-mrethyl 3, 5-Dimethyl 6-Zthy.-3-methy.
6 -n-Propy.- 3-methyl 6-iso-propy.-3 -methyl 2-Ethyl-3, 5-di4methy.
6-sec Butyl-3-methyl 2-iso-Propy.-a. 5-dimet 6-Diethylw~etbyl-3 -metb.
p-Chlorphenol p-Chlorophenol p-Chlorophenol p-Chlorrophenol p-Chlorophenol p-Chlorophenol p-Chlorophenol p-Chlorophenol p-Chlorophenol o-Chlorophenol o-Chlorophonol o-Chlorophenol o-Chlorophenol o-Chlorophenol o-Chlorophonol o-chlorophenol o-Chioropenol p-Ch~torophenol p-Ch:Loropbenol p-ChLorophenoi p-ChlorophenI.
p-CIhlorophenol p-Chlorophenol p-(,hlorophenol p-Chlorophenol fp'-Chlorophenol p-'Chlorophenol p-Chlorophenol p-Chlorophenol hyl p-Chlorophenol Lyl p-Chlorophenol ii I I 6-iso-Propyl-2-ethyl-3-methyl 2-sec Amyl-3, 5-dixnethyl 2-Diethylmethyl-3 ,5-dimetihyl 6-sec Octyl-3-rnethyl p-Bromophenol Methyl Ethyl n-Propyl n-Butyl ~O n-Aniyl sec-Arnyl n-Hexirl cyc2.ohexyl o-Bromophenol p-Chlorophenol p-Chlorophenol p-Chlorophenol p-Chlorophenol p-Bromophenol p-Bromophenol p-Bromophenol p-Bromophenol p-Bromophenol p-Bromophenol p-Bromophenol p-Bromophenol *0t09 0~ oo 09 o 0 o 00~ 0 90 0 0 6 tert-Anyl o-Bromophenol n-Hexyl o-Bromophenol n-Propyl-m,m-Dimethyl o-Bromophenol 2-Phenyl Phenol 4-Chloro-2-methyl phenol 4-chloro-3-rnethyl phenol 4-chloro-3 ,5-diniethyl phenol 2, 4-dichloro-3 ,5-diniet hyl phenol 3, 4, 5,6-tetrabromo-2-methylphonol 2-pentylphenol 4-isopropyl-3-methylphenol 5-chloro-2-hydroxydiphenyl metharie Resorcinol and Its Derivativos Resorcinol Methyl S Ethyl n-Propyl n-Butyl n-Arnyl Resorcinol Reso'c~lnol Resorcinol Resorcinol Resorcinol '00.
n-Hexyl n-Heptyl n1-Octyl n-Nonyl Phenyl Ben zyl Phenylethyl Phenyipropyl p-Chlorobenzyl 5-Chioro 4 '-Chioro -Bromo 4 "-Bromo Resorcinol Resorcinol Resorcinol Resorcinol Resorcinol Resorcinol Resorcinol Resorcinol Resorcinol 4-Dihydroxydiphenyl '1-Dihydroxydiphenyl 4-Dihydroxydiphenyl 4-Dihydroxydiphenyl Bisphenolic compounds Methane Methane Methane Methane Co CC
CC
0.9
C
CC
o
C
Ce'., 0999
C
*0 C Cl Bisphenol A 2, 2' -mthyjlene bis (4-chiorophenol) 2,2' -methylene bis 6-trichlorophcnol) (hexachlorophene) 2,2' -methylene bis (4-chloro-6--bromophenol) his (2-hydroxy-3,5-dichlorophenyl) sulfide 2o is (2-hydroxy-5-chlorobenzyl) sulfide The noncationic antibacterial agent is present in the oral composition in an effective antiplaque amount a~ about 0.0l%-5% by weight, \Preferably about0.3l% ~ee~k~about 0.25-0.5% or about 0.25% to less than and most preferably about 0.25-0,35%, e.g. about in a dentiirice or preferably about 0.03-0.3% by weight, most preferably about 0.03-0.1% in a mouthwash or liquid dentifrice. The antibacterial agent is substantially waterinsoluble, meaning that its solubility iS less than about 1% S by weight in water at 25C and may be even less than about 0.1%.
The preferred halogenated diphenyl other is triclosan.
The preferred phenolic compounds are phenol, thymol,
C
V
I 1 eugenol, hexyl resorcinol and 2,2'methylene bis (4-chloro-6bromophenol). The most preferred antibacterial antiplaque compound is triclosan. Triclosan is disclosed in aforementioned U.S. Patent 4,022,880 as an antibacterial agent in combination with an anticalculus agent which provides zinc ions and in German Patent Disclosure 3532860 in combination with a copper compound. In European Patent Disclosure 0278744 it is disclosed in combination with a tooth desentizing agent containing a source of potassium ions. It is also disclosed as an antiplaque agent in a dentifrice formulated to contain a lamellar liquid crystal surfactant phase having a lamellar spacing of less than nm and which may optionally contain a zinc salt in published European Patent Application 0161898 of Lane et al and in a dentifrice containing zinc citrate trihydrate in published European Patent Application 0161899 to Saxton et al.
o la o e0o o o* on Eat *0 Q The antibacterial-enhancing agent (AEA) which enhances delivery of said antibacterial agert to, and retention thereof on, oral surfaces, is employed in amounts effective to achieve such enhancement within the range in the oral composition of about 0.005% to about preferably about 0.1% to about more preferably about 0.5% to about by weight.
The AEA may be a simple compound, preferably a polymerizable monomer, more preferably a polymer, which latter term is entirely generic, including for example oligomers, homopolymnrs, copolymers of two or more monomers, ionomers, block copolymers, graft copolymers, cross-linked polymers and copolymers, and the like. The AEA may be natural or synthetic, anu water insoluble or preferably water (saliva) soluble or swellable (hydratable, hydrogel forming). It has an (weight) average molecular weight of about 100 to about 1,000,000, preferably about 1,000 to about 1,000,000, mo-e preferably about 2,0C0 or 2,500 to ,o about 250,000 or 500,000.
'ot T The AEA ordinarily contains at least one delivery- °6 enhancing group, which is preferably acidic such as 0 o ea sulfonic, phosphonic, or more preferably phosphonic or *aoe carboxylic, or salt thereof, e.g. alkali metal or ammonium, and at least one organic retention-enhancing group, preferably a plurality of both the delivery-enhancing and ,retention-enhancing groups, which latter groups preferably have the formula wherein X is 0, N, S, SO, SO,, P, S PO or Si or the like, R is hydrophobic alkyl, alkenyl, acyl, aryl, alkaryl, aralkyl, heterocyclic or their inertsubstituted derivatives, and n is zero or 1 or more. The aforesaid "inert-substituted derivatives", are intended to include substituents on R which are generally nonhydrophilic and do not significantly interfere with the 0^ desired functions of the AEA as enhancing the delivery of the antibactc-rial agent to, and retention thereof on, oral surfacfis such as halo, e.g. Cl, D~r, I, and carbo and the like. 'Illustrations of such re tent-,on- Cnhanc ing groups are tabulated below.
n X -X, 0 methyl, ethyl, propyl, butyl, isobutyl, t-butyl cyclohexyl, allyl, benzyl, phenyl, chlorophenyl, xylyl, pyridyl, furanyl, acetyl, benzoyl, butyryl, terephthaloyl, etc.
1 0 ethoxy, benzyloxy, thioacetoxy, phenoxy, carboethoxy, carbobenzyloxy, etc, N ethylamino, diethylanino, propylamido, benzylamino, benzoylamido, phenylacetamido, etc.
S thiobutyl, thi.'oisobutyl. thioallyl, thiobenzyl, thiophenyl, thico'propionyl, phenylthioacetyl, thiobenzoyl, etc.
So butylsulfoxy, allylsulfoxy, benzylsuifoxy, phenylsulfoxy, etc.
So, butylsulfonyl, allylsulfonyl, benzylsulfonyl, phenylsulfonyl, etc.
P diethylphosphinyl, ethylvinylphosphinyl, ethylallylphosphinyl, ethylbenzylphosphinyl, ethylphanylphosphinyl, etc.
PO diethylphosphinoxy, ethylvinylphosphino.xy, methylallylphosphinoxy, me thy lbenzylpho sphinoxy, methylphenylphosphinoxy, etc.
Si trirnethylsilyl, dime thy lbu tyls ilyl, dirnethylbenzylsilyl, dimethylvinylsilyl, dimethylallylsilyl, etc.
o 00:~ 00 0 0~ 00* 00 00 0 0000 *0,0 It
II
As employed herein, the delivery-enhancing group refers to one which attaches or substantively, adhesively, cohesively or otherwise bonds the Al-A .arrying the antibacterial agent) to oral tooth and gum) surfaces, thereby "delivering" the antibacterial agent to such surfaces. The organic retention-enhancing group, generally hydrophobic, attaches or otherwise bonds the antibacterial agent to the AEA, thereby promoting retention of the antibacterial agent to the AEA and indirectly on the oral IC surfaces. In some instances, attachment of the antibacterial agent occurs through physical entrapment thereof by the AEA, especially when the AEA is a crosslinked polymer, the structure of which inherently provides increased sites for such entrapment. The presence of a higher molecular weight, more hydrophobic cross-liniking moiety in the cross-linked polymer still further promotes the physical entrapment of the antibacterial agent to or by the cross-linked AEA polymer.
Preferably, the AEA is a anionic polymer o an comprising a chain or backbone containing repeating units *o each preferably containing at least one carbon atom and o co i o preferably at least one directly or indirectly pendent, at monovalent delivery-enhancing group and at least one "0O0 directly or indirectly pendent monovalent retentio l enhancing group geminally, vicinally or less preferably otherwise bonded to atoms, preferably carbon, in the chain.
0 °Less preferably, the polymer may contain delivery-enhancing ,A o, groups and/or retention-enhancing groups and/or other Oi divalent atoms or groups as links in the polymer chain o 3 instead of or in addition to carbon atoms, or as crosslinking moieties.
It will be understood that any examples or illustrations of AEA's disclosed herein which do not contain 12 -i both delivery-enhancing groups and retention enhancing groups may and preferably should be chemically moAified in known manner to obtain the preferred AEA' s containing both such groups and preferably a plurality of each such groups.
In the case of the preferred polymeric AEA's, it is desirable, for maximizing substantivity and delivery of the antibacterial agent to oral surfaces, that the repeating units in the polymer chain or backbone containing the acidic delivery enhancing groups constitute at least about lo 10%, preferably at least about 50%, more preferably at least about 80% up to 95% or 100% by weight of the polymer.
According to a preferred embodiment of this invention, the AEA comprises a polymer containing repeating units which one or more phosphonic acid deliveryenhancing groups are bonded to one or more carbon atoms in tht. polymer chain. An example of such an AEA is poly (vinyl phosphonic acid) containing units of the formula: I -[CH
POH,
A .Q which however does not contain a retention-enhancing group.
group of the latter type would however be present in poly Si, (1-phosphonopropene) with unita of the formula: II -[CH -CH]- CH, POaH, A preferred phosphonic acid-containing AEA for use herein .Ls poly (beta styrene phosphonic acid) containing units of S< the formula: III CH]- Ph PO,H, do wherein Ph is phenyl,, the phosphonic delivery-enhancing group and the phenyl retention-enhancing group being bonded on vicinal carbon atoms in the chain, or a copolymer of beta styrene phosphonic acid with vinyl phosphonyl chloride 13
I
Qi~" I 0 f having the units of formula III alternating or in random association with units of formula I above, or poly (alpha styrene phosphonic tcid) containing units of the formula: IV -[CH C Ph POJH, in which the delivery and retention enhancing groups are geminally bonded to the chain.
These styrene phosphonic acid polymers and their copolymers with other inert ethylenically unsaturated S monomers generally have molecular weights in the range of al ut 2,000 to about 30,000, preferably about 2,500 to about 10,000. Such "inert" monomers do not significantly interfere with the intended function of any copolymer employed as an AEA herein.
Other phosphonic-containing polymers include, for example, phosphonated ethylene having units of the formula.
V -[CH 2 ,),CHPO3H 2 where n may for example be an integer or have a value giving the polymer a molecular weight of about 3,000; and sodium -0 poly (butene-4,4-diphosphonate) having units of the formula: VI S CH (P0.Na.) 2 and poly (allyl bis (phosphonoethyl amine) having units of the formula: VII CH N (POal,)1 Other phosphonated polymers, for example poly (allyi phosphono acetate), phosphonated polymethacrylate, etc. and the geminal diphosphonate polymers disclosed in EP Publication 0321233 may be employed herein as AEA' s, provided of course that they contain or are modified to contain the above-defined organic retention-enhancing groups.
09 0 prq eo, 0 a1 >0
*C
~be In an aspect of the invention, the oral composition comprises an orally acceptable vehicle, an effective antiplaque amount of a substantially water insoluble noncationic antibacterial agent and an antibacterial-enhancing agent which has an average molecular weight or about 1,000 to about 1,000,000, contains at least one delivery enhan.ing functional group and at least one organic retention enhancing group,said agent containing said groups being free from or substantially free from water soluble alkali metal or ammonium synthetic anionic linear fO polymer polycarboxylate salt having a molecul.! weight of about 1,000 to about 1,000,000.
1 Ua It i i According to another preferred embodiment, the AEA may comprise a synthetic anionic polymeric polycarboxylate.
Although not used in the present invention to coact with polyphosphate anticalculus agent, synthetic anionic polymeric polycarboxvlate having a molecular weight of about 1,000 to about 1,090,000, preferably about 30,000 to about 500,000, has been used as an inhibitor of alkaline phosphatase enzyme in optimizing anticalculus effectiveness of linear molecularly dehydrated polyphosphate saltes, as disclosed in U.S. Patent 4,627,977 to Gaffar et al. Indeed, in published British Patent Publication 22 00551, the polymeric polycarboxylate is disclosed as an optional ingredient in oral compositions containing linear molecularly dehydrated polyphosphate salts and substantially water-insoluble noncationic antibacterial agent. It is further observed, in the context of the present invention that such polycarboxylate is markedly effective to enhance delivery and retention of the nonionic antibacterial, antiplaque agent to dental surfaces when another gngred-i=nt .0 ingredient with which the polymric polycarboxylate coacts /is absent; for instance, when the ingredient with which the polymeric polycarboxylate coacts is especially the Snoncationic antibacterial agent.
Synthetic anionic polymeric polycarboxylates and their complexes with various cationic germicides, zinc and 6, magnesium have been previously disclosed as anticalculus agents per se in, for example, U.S. Patent No. 3,429,963 to Shedlovsky; U.S. Patent No. 4,152,420 to Gaffar; U.S. Patent No. 3,956,480 to Dichter et al; U.S. Patent No. 4,138,477 to Gaffar; and U.S. Patent No. 4,183,914 to Gaffar et al.
It is to be understood that the synthetic anionic polymeric polycarboxylates so disclosed in these several patents when 16 PE V l 4 containing or modified to contain retention-enhancing groups are operative in the compositions and methods of this invention and such disclosures are to that extent incorporated herein by reference thereto.
The synthetic anionic polymeric polycarboxylates employed herein are well known, being often employed in the form of their free acids or preferably partially or more preferably fully neutralized water soluble alkali metal potassium and preferably sodium) or ammonium salts.
Preferred are 1:4 to 4:1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, preferably methyl vinyl ether/maleic anhydride having a molecular weight of about 30,000 to about 1,000,000, most preferably about 30,000 to about 500,000.
These copolymers are available, for example, as Gantrez e.g.
AN 1,39 500,000), AN 119 250,000); and preferably S-97 Pharmaceutical Grade 70,000), of GAF Corporation, a. Other AEA operative polymeric polycarboxylates Sa containing or modified to contain retention-enhancing groups include those disclosed in U.S. Patent No. 3,956,480 referred to above, such as the 1:1 copolymers of maleic o anhydride with ethyl acrylate, hydroxyethyl methacrylate, Nvinyl-2-pyrollidone, or ethylene, the latter being available, for example, as Monsanto EMA No. 1103, M.W.
10,000 and EMA Grade 61, and 1:1 copolymers of acrylic acid with methyl or hydroxyethyl methacrylate, methyl or ethyl acrylate, isobutyl, isobutyl vinyl ether or N-vinyl-2pyrrolidone.
Additional operative polymeric polycarboxylates disclosed in above referred to U.S. Patent No. 4,138,477 and 4,183,914, containing or modified to contain retentionenhancing groups include copolymers of maleic anhydride with 17 i styrene, isobutylene or ethyl vinyl ether, polyacrylic, polyitaconic and polymaleic acids, and sulfoacrylic oligomers of M.W. as low as 1,000, available as Uniroyal ND- 2.
Suitable generally are retention-enhancing groupcontaining polmerized olefinically or ethylenically unsaturated carboxylic acids containing an activated carbonto-carbon olefinic double bond which readily functions in polymerization because of its presence in the monomer molecule either in the alpha-beta position with respect to a carboxyl group or a part of a terminal methylene grouping.
Illustrative of such acids are acrylic, methacrylic, ethacrylic, alpha-chloroacrylic, crotonic, beta-acryloxy propionic, sorbic, alpha-chlorsorbic, cinnamic, beta- <"yrylacrylic, muconic, itaconic, citraconic, mesaconic, .lutaconic, aconitic, alpha-phenylacrylic, 2-benzyl acrylic, 2-cyclohexylacrylic, angelic, umbellic, fumaric, maleic acids and anhydrides. Other different olefinic monomer copolymerizable with such carboxylic monomers include vinylacetate, vinyl chloride, dimethyl maleate and the like.
Copolymers contain sufficient carboxylic salt groups for water-solubility.
o Also useful herein are so-called carboxyvinyl polymers o disclosed as toothpaste components in U.S. 3,980,767 to Chown et al; U.S. 3,935,306 to Roberts et al; U.S. 3,919,409 o oo o* to Perla at al; U.S. 3,911,904 to Harrison, and U.S.
oo 3,711,604 to Colodney at al. They are commercially 0o00 available, for example, under the trademarks Carbopol 934, 940 and 941 of B.F. Goodrich, these products consisting C) essentially of a colloidally water-soluble polymer of *Q O polyacrylic acid crosslinked with from about 0.75% to about oO 0 o o 2.0% of polyallyl sucrose or polyallyl pentaerythritol as cross linking agent, the cross-linked structure and cross- *o 6 0. 18 0 ifw* *il
L
linkages providing the desired retention enhancement by hydrophobicity and/or physical entrapment of the antibacterial agent or the like. Polycarbophil is somewhat similar, being poly acrylic acid cross-linked with less than 0.2% of divinyl glycol, the lower proportion, molecular weight and/or hydrophobicity of this cross-linking agent tending to provide little or no retention enhancement. exemplifies a more effective retention-enhancing cross-linking agent.
1 The synthetic anionic polymeric polycarboxylate component is mainly a hydrocarbon with option halogen and 0containing substituents and linkages as present in, for example ester, ether and OH groups, and is employed in the insant compositions in approximate weight amounts of 0.05 to preferably 0.05 to more preferably 0.1 to 2%.
o oo so o o 0* p I II" *II
I
(1 I 19 trl ICC
':E
ii The AEA may also comprise natural anionic polymeric polycarboxylates containing retention-enhancing groups.
Carboxyrnethyl cellulose and other binding agents gums and filmformers devoid of the above-defined delivery-enhancing and/or retention-enhancing groups are ineffective as AEA's.
As illustrative of AEA's containing phosphinic acid and/or sulfonic acid delivery enhancing groups, there may be mentioned polymers and copolymers containing units or moieties derived from the polymerization of vinyl or allyl phosphinic and/or JO sulfonic acids substituted as needed on the 1 or 2 (or 3) carbon atom by an organic retention-enhancing group, for example having the formula defined above. Mixtures of these monomers may be employed, and copclymers thereof with one or more inert polymerizable ethylenically unsaturated monomers such as those described above with respect to the operative synthetic anionic polymeric polycarboxylates. As will be noted, in these and other polymeric AEA's operative herein, usually only one acidic delivery-enhancing group is bonded to any given carbon or other atom in the polymer backbone or branch thereon. Polysiloxanes containing or modified to contain pendant delivery-enhancing groups and retention enhancing groups may also be employed as AEA's herein. Also offective as AEA's herein are ionomers containing or modified to contain delivery-and retentionenhancing group. Io:omers are described on pages 546-573 of .4 the Kirk Othmer Encyclopedia of Chemical Technology, third t edition, Supplement Volume, John Wiley Sons, Inc. copyright 198/1, which description is incorporated herein by reference.
t fAlso effective as AEA's herein, provided they contain or are modified to contain retention-enhancing groups, are polyesters, 3 polyurethanes and synthetic and natural polyamides including proteins and proteinaceous materials such as collagen, poly f ct (arginine) and other polymerized amino acids.
tc t i C C I t C
L.
I[n an aspect of the present invention the AEA which has an average molecular weight of about 1,000 to about 1,000,000, contains at least one delivery enhancing functional group and at least one organic retention enhancing group, said agent containing said groups being free from or substantially free from water soluble alkali metal or ammonium synthetic anionic linear polymer polycarboxylate salt having a molecular weight of about 1,000 to about 1,000,000.
In the present invention a preferred oral composition is a dentifrice containing about 0.3% by weight of the antibacterial agent t1riclosan) and about 1.5-2% by weight of the polycarboxylate as AEA.
Without being bound to a theory, it is believed that the AEA, especially polymeric AEA, is generally an anionic film forming material and is thought to attach to tooth surfaces and form a continuous film over the surfaces, thereby preventing bacterial attachment to tooth surfaces.
It. is possible that the noncationic antibacterial agent Sforms a complex or other form of association with the AEA, thus forming a film ot a complex or the like over tooth surfaces. The film forming propc!ty of the AEA and o f the ABA. 1 the enhanced delivery and retention of the antibacterial agent on tooth surfaces due to the AEA appears to make tooth 00surfaces unfavourable for bacterial accumulation particularly since the direct bacteriostatic action of the Cantibacterial agent controls bacterial growth. Therefore, through the combination of three modes of actions: 1,) 9 enhanced delivery, 2) long retention time on tooth surfaces, and 3) prevention of bacterial attachnenr; to tooth surfaces, I *4 the oral composition is made efficacious for reducing plaque. similar antiplaque effectiveness is attained on TL 21 sea":4 soft oral tissue at or near the gum line.
In accordance with the present invention, the orally acceptable vehicle is effective to enable the substantially water-insoluble noncationic antibacterial agent to dissolve in saliva in an effective antiplaque amount.
In the oral preparation, an orally acceptable vehicle includes a water-phase with humectant present. In a gel dentifrice, typically containing about 5-30% by weight of a siliceous polishing agent, water is typically present in I) amount of at least about 3% by weight, generally about 3and humectant, preferably glycerine and/or sorbitol typically total about 6.5-75% or 80% by weight of the oral gel dentifrice composition. Reference hereto to sorbitol refers to the material typically as available commerically in 70% aqueous solutions.
The gel dentifrices, when the amount of antibacterial agent is about 0.25-0.35% by weight, do not require a further ingredient in the oral vehicle to solubilize the antibacterial agent, although the presence of -0 such so±ubilizing agent is optional. When the amount of antibacterial agent is below about 0.25% by weight, e.g.
about 0.01 up to about 0.25% by weight, solubilizing agent wa* therefore should be present in order to assure sufficient o solubilization in saliva for antiplaque effectiveness. When o. the amount of antibacterial agent is above about 0.35% by 4 o, weight, e.g. about 0.35 to about 0.5% or more, say ***solubilizing agent therefore should be present since otherwise a substantial part of the antibacterial agent would remain insoluble.
When the oral composition is a dentifrice containing about 30-75% by weight of a dentally acceptable polishing agent, the presence of such solubilizing agent is also optional.
I t 22 L "1 IC~i-- rrr~e When the oral composition is a mouthwash or liquid dentifrice, the oral vehicle includes at least one of a surface-active agent, a flavoring oil or a non-toxic alcohol each of which assists in dissolving the antibacterial agent and again the presence of such solubilizing agent is optional.
When solubilizing agent is present in oral compositions of the instant invention, it is typically in amount of about 0.5-20% by weight, with as little as about k) 0.5% i y weight being sufficient when the amount of substantially water-insoluble non-cationic antibacterial agent is low, say up to about 0.3% by weight. When higher amounts such as least about 0.5% by weight of antibacterial agent are present and particularly when siliceous polishing agent is also present in amount of about 5-30% by weight, it is desirable that at least about 5% by weight, typically up to about 20% or more by weight, of the solubilizing agent be present. It is noted that there may be a tendency for the dentifrice to separate into liquid and solid portions when S more than about 5% by weight of the solubilizing agent is present.
The agent which is or may be present to solubilization of the antibacterial agent in saliva may be incorporated in the water-humectant vehicle. Such solubilizing agents include humectant polyols such as 0 Spropylene glycol, dipropylene glycol and hexylene glycol, eo a I cellosolves such as methyl ccllosolve and ethyl cellosolve, lc, vegetable oils and waxes containing at least about 12 carbons in a straight chain such as olive oil, castor oil S and petrolatum and esters such as amyl acetate, ethyl acetate and benzyl benzoate. As used herein, "propylene glycol" includes 1,2-propylene glycol and 1,3-propylene glycol. Significant amounts of polyethylene glycol t t2 4 23 Sii r: *i i ~I -1 particularly of molecular weight of 600 or more should be avoided since polyethylene glycol effectively inhibits the antibacterial activity of the noncationic antibacterial agent. For instance, polyethylene glycol (PEG) 600 when present with triclosan in a weight ratio of 25 triclosan:l PEG 600 reduces the antibacterial activity of triclosan by a factor of about 16 from that prevailing in the absence of the polyethylene glycol.
In accordance with aspects of this invention, oral I0 composition dentifrice may ne substantially gel in character, such as a gel dentifrice. Such gel oral preparations contain siliceous dentally polishing material Preferred polishing materials include crystalline silica having partic.- sized of up to about 5 microns, a mean particle size of up to about 1.1 mic'ons, and a surface area of up to about 50,000 silica gel or colloidal silica and complex amorphous alkali metal aluminosilicate.
When visually clear or opacified gels are employed, a polishing agent of colloidal silica, such as ?O those sold under the trademark SYLOID as Syloid 72 and Syloid 74 or under the trademark SANTOCEL as Santocel 100 or alkali metal aluminosilicate complexes (that is, silica <O°"jo containing alumina combined in its matrix) are particularly o 0 S* "useful, since they are consistant with gel-like texture and o have refractive indices close to the refractive indices of o gelling agent-liquid (including water and/or humectant) oOe S| o. systems commonly used in dentifrices.
too The polishing material is generally present in the oral composition dentifrices such as toothpaste or gel compositions in weight concentrations of about 5% to about In the aspect of this invention wherein the oral preparation is a dentifrice, an orally acceptable vehicle S: 24 rr !4 including a water-phase with humectant which is preferably glycerine and/or sorbitol is present, wherein water is present typically in amount of about 15-35% or 40% by weight and glycerine and/or sorbitol typically total about 20-75% by weight of the oral preparation dentifrice, more typically about 25-60%. Reference hereto to sorbitol again refers to the material typically as available commercially in aqueous solutions.
In this invention, the oral dentifrice composition tO may be substantially pasty in character, such as a toothpaste (dental cream), although when siliceous polishing agent is employed (which is not generally the case, since such material is typically not employed in amount above about 30% by weight) it can be gel in character. The vehicle of the oral composition dentifrice contains dentally acceptable polishing material, examples of which polishing materials are water-insoluble sodium metaphosphate, potassium mataphosphate, tricalcium phosphate, dihydrated dicalcium phosphate, anhydrous dicalcium phosphate, calciui a carbonate, aluminum silicate, hydrated alumina, silica, bentonite, and mixtures thereof with each other or with hard polishing materials such as calcined alumina and zirconium silicate, material including the particulate thermosetting resins described in U.S. Pat. No. 3,070,510 issued Dec. 664 1962, such as melamine- phenolic and urea-formaldehydes, and a i cross-linked polyepoxides and polyesters. Preferred i, polishing materials include insoluble sodium metaphosphates, B' dicalcium phosphate and hydrated alumina.
Many of the so-called "water-insoluble" polishing materials are anionic in character and also include small amounts of soluble material. Thus, insoluble sodium metaphosphate may b formed in any suitable manner as illustated by Thorpe's Dictionary of Applied Chemistry, 4 Volume 9, 4th Edition, pp. 510-511. The forms of insoluble sodium metaphosphate known as Madrell's salt and Kurrol;s salt are further examples of suitable materials. These metaphosphate salts exhibit only a minute solubility in water, and therefore are commonly referred to as insoluble metaphosphates (IMP). There is present therein a minor amount of soluble phosphaste material as impurities, usually a few percent such as up to 4% by weight. The amount of soluble phosphate material, which is believeed to include a t0 soluble sodium trimetaphosphate in the case insoluble metaphosphate, may be reduced or eliminated by washing with water if desired. The insoluble alkali metal metaphosphate is typically employed in powder form of a particle size such that no more than 1% of the material is larger than 37 microns.
Hydrated alumina is an example of a polishing material which is essentially nonionic in nature. Typically, it is small in particle size, at least about 85% of the particules are smaller than 20 microns and is such as that S classified as gibbsite (alpha alumina trihydrato) and normally represented chemically as A1 2 0,.3H20 or Al(OH)3.
The average particle size of gibbsite is generally about 6 to 9 microns. A typical grade has the following size distribution: a 40 o o ''4 0 4 lit Ooi Micron <20 Percent 94-99 85-93 56-67 28-40 The polishing material is generally present in the cream paste or gel compositions in weight contracts of about 26 4441 I Itrr to about Toothpastes or dental cream dentifrices as well as gel dentifrices typically contain a natural or synthetic thickener or gelling agent in proportions of about 0.1 to about 10%, preferably about 0.5 to about A suitable thickener is synethtic colloidal magnesium alkali metal silicate complex -Lay available, for example, as Laponite CP, S 2002, D) marketed by Laporte Industries Limited. Laponite D analysis shows, aoproximately by weight, 58.00% SiO2, 25.40% MgO, 3.05% Na20, 0.95S Li 2 O, and some water and trace metals. Its true specific gravity is 2.53 and it has an apparent bulk density at 8% moisture) of Other suitable thickeners or gelling agents or thickeners include Irish moss, iota-carrageenan, gum tragacanth, starch, polyvinylpyrrolidone, hydroxyethpropylcellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl .ellulose, hydroxyethyl cellulose available as Natrosol), sodium carboxymethyl cellulose, and particularly J0 when siliceous polishing agent is present, colloidal silica such as those available as finely grows Syloid 244 or Sylodent In the aspect of the present invention wherein the Go ,oral composition is a mouthwash or liquid dentifrice, O, substantially liquid in character and is the vehicle 0 lot particularly in a mouthwash is typically a water-alcohol S, mixture. Generally, the weight ratio of water to alcohol is in the range of from about 1:1 to about 20:1, preferably about 3:1 to 10:1 and more preferably about 4:1 to about 6:1. The total amount of water-alcohol mixture in this type of preparation is typically in the range of from about 70 to about 99.9% by weight. The alcohol is a non-toxic alcohol such as ethanol or isopropanol. Humectant such as glycerine 27 L>
P_
-llril and sorbitol may be present in amount of about 10-30% by weight. Liquid dentifrices typically contain about 50-85% of water, may contain about 0.5-20% by weight of non-toxic alcohol and may also contain about 10-40% by weight of humectant such as glycerine end/or sorbitol. Reference hereto sorbitol refers to the material typically as available commercially in 70% aqueous solutions. Ethanol is the preferred non-toxic alcohol. The alcohol is belieed to assist in dissolving the water-insoluble non-cationic (0 antibacterial agent as, it is believed also does flavoring oil.
As indicated, the noncationic antibacterial agent is substantially water-insoluble. However, in the present invention, with the AEA, such as polycarboxylate, present in the mouthwash or liquid dentifrice, organic surface-active agent, flavoring oil or non-toxic alcohol are believed to aid dissolving the antibacterial agent to assist it to reach soft oral tissue at or near the gums as well as tooth surfaces. Organic surface-active agents and/Or flavoring oils may also assist dissolving the antibacterial agents as optional ingredients in oral dentifrice compositions.
Organic surface-active agents are also used in the compositions of the present invention to achieve increased prophylactic action, assist in achieving thorough and complete dispersion of the antiplaque antibacterial agent throughout th( oral cavity, and render the instant compositions more cosmetically acceptable. The organic surface-active material is preferably anionic, nonionic or ampholytic in nature, and it is preferred to employ as the O surface-active agent a detersive material which imparts to the composition detersive and foaming properties. Suitable examples of anionic surfactants are water-soluble salts of higher fatty acid monoglyceride monosulfates, such as the 0J a a 0 C C
I
sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids, higher alkyl sulfates such as sodium lauryl sulfate, alkyl aryl sulfonates such as sodium dodecyl benzene sulfonate, higher alkyl sulfoacetates, higher fatty acid esters of 1,2-dihydroxy propane sulfonate, and the substantially saturated higher aliphatic acyl amides of lower aliphatic amino carboxylic acid compounds, such as those having 12 to 16 carbons in the fatty acid, alkyl or acyl radicals, and the like. Examples of the last mentioned amides are N-lauroyl sarcosine, and the sodium, potassium, and ethanolamine salts of N-lauroyl, N-myristoyl, or N-palmitoyl sarcosine which should be substantially free from soap or similar higher fatty acid material. The use of these sarcosinate compounds in the oral compositions of the present invention is particularly advantageous since these materials exhibit a prolonged and marked effect in the inhibition of acid Formation in the oral cavity due to carbohydrate breakdown in addition to exerting some reduction in the solubility of tooth enamel in S acid solutions. Examples of water-soluble nonionic surfactants are condensation products of ethylene oxide with various reactive hydrogen-containing compounds reactive o therewith havina long hydrophobic chains aliphatic "o chains of about 12 to 20 carbon atoms), which condensation products ("ethoxamers") contain hydrophilic polyoxyethylene o* moieties, such as condensation products of poly(ethylene ,I oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols sorbitan monosterate) and polypropyleneoxide Pluronic materials).
O Surface active agent is typically present in amount of about 0.5-5% by weight, preferably about 1-2.5%.
When the oral composition is a liquid dentifrice the natural or synthetic thickener or gelling agent as descried t 4 I 29 is typically present in proportions of about 0.1 to about preferably about 0.5 to about Generally liquid dentifrices do not contain a polishing agent. However, as described in U.S. Patent 3,506,757 to Salzmann, about 0.3-2.0% by weight of a polysaccharide of high molecular weight in excess of 1,000,000 containing mannose, glucose, potassium glucuronate and acetyl moieties in the approximate ratio of 2:1:1:1, as suspending and thickening agent can be employed in a liquid j1 dentifrice, which then may also contain about 10-20% of a polishing material such as hydrated alumina, dicalcium phosphate dihydrate, calcium pyrophosphate, insoluble sodium metaphosphate, anhydrous dicalcium phosphate, calcium carbonate, magnesium carbonate, magnesium oxide, silica, mixtures thereof, and the like.
Without being bound to a theory whereby the advantages of this invention are achieved, it is believed that an aqueous, humectant vehicle is normally solubilized in surfactant micelles in the mobile phase (that is, not a including gelling agent and polishing agent, if present in a dentifrice formula). The mobile phase solution of ,o dentifrice during use can become diluted with saliva which causes triclosan to precipitate. Thus, it is found that even in the absence of a special solubilizing material for o triclosan, when the amount of triclosan is about 0.25%-0.35% by weight and AEA such as the polycarboxylate is present, sufficient triclosan is present to exert an excellent L* antiplaque effect on the soft tissues at the gum line.
Similar remarks apply to other water-insoluble noncationic antibacterial agents herein described.
The oral composition dentifrice may also contain a source of fluoride ions or fluorine-providing component, as anticaries agent in amount sufficient to supply about t' t 1i 1 -i ~LI~L~ i ppm to 5000 ppm of fluoride ions. These compounds may be slightly soluble in water or may be fully water-soluble.
They are characterized by their ability to release fluoride ions in water andy by substantial freedom from undesired reaction with other compeunds of the oral preparation.
Among these materials are inorganic fluoride salts, such as soluble alkali metal, alkaline earth metal salts, for example, sodium fluoride, potassium fluoride, ammonium fluoride, calcium fluoride, a copper fluoride such as (0 cuprous fluoride, zinc fluoride, barium fluoride, sodium flourosilicate, ammonium flourosilicate, sodium fluorczirconate, ammonium fluorozirconate, sodium monofluorophosphate, aluminum mono-and di-fluorophosphate and sodium calcium pyrophosphate. Alkali metal and tin fluorides, such as sodium and stannous fluorides, sodium monofluorophosphate (MFP) and mixtures thereof, are preferred.
The amount of fluorine-providing compound is dependent to some extent upon the type of compound, its k solubility, and the type of oral prepartion, but it must be Q.4 0 2 a non-toxic amount, generally about 0.0005 to about 3.0% in the preparation. In a dentifrice preparation, e.g. dental S e ao gel and an amount of such compound which releases up to 00 0 °4 about 5,000 ppm of F ion by weight of the preparation is considered satisfactory. Any suitable minimum amount of such compound may be used, but it is preferable to employ sufficent compound to release about 300 to 2,000 ppm, more preferably about 800 to about 1,500 ppm of fluoride ion.
Typically, in the cases of alkali metal fluorides, this component is present in an amount up to about 2% by weight, based on the weight of the preparation, and preferably in the race of about 0.05% to In the case of sodium monofluorophosphate, the compound may be present in an t 111 111 Et t A -P ~irrrrrri amount of about more typically about 0.76%.
It will be understood that, as is conventional, the oral preparations are to be sold or otherwise distributed in suitable labelled packages. Thus a dentifrice gel will usually be in a collapsible tube typically aluminum, lined load or plastic, or other squeeze, pump or pressurized dispenser for metering out the contents, having a label describing it, in substance, as a dentifrice gel or the like.
Various other materials may be incorporated in the oral preparations of this invention such as whitening agents, preservatives, silicones, chlorophyll compounds and/or ammoniated material such as urea, diammonium phosphate, and mixtures thereof. These adjuvants, where present, are incorporatd in the preparations in amounts which do not substantially adversely affect the properties and characteristics desired. Significant amounts of zinc, magnesium and other metal salts and materials, which are generally soluble and which would complex with active 2o components of the instant invention are to be avoided.
o Any suitable flavoring or sweetening material may S0 4 o. also be employed. Examples of suitable flavoring e a i constituents are flavoring oils, e.g. oil of spearmint, 0 0 4 peppermint, wintergreen, sassafras, clove, sage, euclyptus, o majoram, cinnamon, lemon, and orange, and methyl salicylate.
Suitable sweetening agents include sucrose, lactose, maltose, xylitol, sodium cyclamate, perillartine, AMP (aspartyl phenyl alanine, methyl ester), saccharine and the Slike. Suitably, flavor and sweetening agents may each or S together comprise from about 0.1% to 5% more of the preparation. Moreover, like the surface-active agent, flavoring oil is believed to aid the dissolving of the antibacterial agent, together with or even in the absence of tIt*32 i l 32 l ln surface-active agent.
In the preferred practice of this invention an oral composition of the present invention is preferably applied regularly to dental enamel and soft oral tissues, particularly at or near the gum line, such as every day or every second or third day or preferably from 1 to 3 times daily, at a pH of about 4.5 to about 9 or 10, generally about 5.5 to about 8, preferably about 6 to 8 and most preferably about 6.5 to about 7.5, for at least 2 weeks up (O to 8 weeks or more up to lifetime. Even at such pH below enamel is not decalcified or otherwise damaged. The pH can be controlled with acid citric acid or benzoic acid) or base sodium hydroxide) or buffered as with sodium citrate, benzoate, carbonate or bicarbonate, disodium hydrogen phosphate, sodium dihydrogent phosphate, etc.).
The compositions of this invention can be incorporated in lozenges, or in chewing gum or other products, e.g. by stirring into a warm gum base or coating the outer surface of a gum base, illustrative of which may O be mentioned jelutong, rubber latex, vinylite resins, etc., o desirably with conventional plasticizers or softeners, sugar or other sweeteners or carbohydrates such as glucose, sorbitol and the like.
*woo 0 4o 94o 995144 e4 33 1
F
*Q The Eollowing examples are further illustrative of the nature of the present invention, but it is understood that the invention is not limited thereto. All amounts and proportions referred to herein and in the appended claims are by weight, unless otherwise indicated.
EXAMPLE 1 The following dentifrice is prepared: Parts A B \0 Glycerine 10.00 Propylene Glycol 10.00 Sorbitol 25.00 25.00 Iota carrageenan 0.60 0.60 Gantrez S-97 2.00 2.00 Sodium Saccharin 0.40 0.40 Sodium Fluoride 0.243 0.243 Sodium Hydroxide 1.00 1.00 Titanium Oxide 0.50 0.50 o, Silica Polishing Agent (Zeodent 113) 20.00 20.00 009 Silica Thickener (Sylox 15) 5.50 5.50 Sodium Lauryl Sulfate 2.00 2.00 SWater 31.507 31.507 Triclosan 0.30 0.30 Flavor Oil 0.95 0.95 t 3 34 t
I
The above dentifrice A delivers Triclosan to the teeth and soft gum tissue essentially as well as dentifrice B containing a special solubilizing agent for Triclosan. In other words, a special solubilizing agent i; not required for the dentifrice of the present invention to be effective. Further, a corresponding dentifrice in which the Gantrez polycarboxylate is absent is substantially poorer in delivering Triclosan.
In the foregoing example, improved results may also be obtai.ed by replacing triclosan with other antibacterial agents \O herein described such as phenol, thymol, eugenol and 2.2'methylene bis (4-chloro-6-bromophenol) and/or by replacing Gantrez with other AEA's such as a 1:1 copolymer of maleic anhydride and ethyl acrylate, sulfoacrylic oligomer, Carbopols 934), and polymers of alpha or beta-styrenephosphonic acid monomers and copolymers of these monomers with each or with other ethylenically unsaturated polymerizable monomers such as vinyl phosphonic acid.
o e 09 9 o 00 o 010 9 1 e
JL.L(
EXAMPLE 2 The following liquid phase dentifrice solutions are tested for uptake and retention of triclosan on saliva coated HA disks following the test procedures described in Example with
A
the indicated results: Ingredients Sorbitol (70% solution) Glycerol I0 Propylene Glycol
SLS
NaF Flavor Oil Triclosan Water A B 30.0 30.0 9.5 9.5 0.5 0.5 20.0 20.0 0.243 0.243 0.95 0.95 0.3 0.3 56.507 54.507
PARTS
C
30.0 9.5 0.5 20.0 0.243 0.95 0.3 54.507
D
30.0 20.0 0.243 0.95 0.3 54.507 o oo or 0 o o~ro S01 0000 Poly (beta-styrenephosphonic acid) Poly (alpha-styrenephosphonic acid) Polyvinyl Alcohol Adjusted to pH 6,5 with NaOH Triclosan Uptake in \A ';Igs Micrograms on Saliva Coated> Retention of Triclosan on Saliva Coated HA Disks After: Initial minutes 1 hour 3 hours 31.0 174.0 86.0 36.0 183.0 136.0 105.0 83.0 0 4 At t C -L L The above results show that solution containing polyvinyl alcohol, not an AEA hereunder, produces a triclosen uptake of only 36.0, quite similar to the 31.0 uptake of the control solutic without additive. In contrast, solution with poly (alpha-styrenephosphonic acid) produces an uptake of 86.0, more than double that of solutions and and solution with poly (beta-styrenephosphonic acid) produces an uptake about 5 times that of solutions and tending to indicate further that vicinal substitution of the delivery- IO enhancing group yields superior results. The above results also show the surprisingly good retention of triclosan on the HA disks over time obtained with solution containing poly (beta-styrenephosphonic acid (M.W's about 3,000 to 10,000).
EXAMPLE 3 The effect of synthetic anionic linear polycarboxylate on the uptake, retention to and release from tooth surfaces of water-insoluble noncationic antibacterial agent is assessed in vitro on a saliva coated hydroxyapatite disk and on exfoliated buccal epithelial cells. The in vitro assessments are o0 e o* -e3 correlatable to in vivo delivery, and retention on oral surfaces.
4 °0 For the test of delivery of antibacterial agent to a o saliva coated hydroxyapatite disk, hydroxyapatite (HA) obtained 0 from the Monsanto Co. is washed extensively with distilled water, collected by vacuum filtration, and permitted to dry overnight at 37°C. The dried HA is ground into a powder with a mortar and pestle. 150.00 mgs of HA are placed into the chamber of a KBr pellet die (Barnes Analytical, Stanford, CT.) and compressed or 6 minutes at 10,000 pound in a Carver Laboratory press. The resulting 13 mm disks are sintered for 4 hours at 800°C in a Thermolyne furnace. Parafilm stimulated whole saliva is collected into an ice-chilled glass beaker. The saliva is clarified by centrifugation at 15,000 Xg (times gravity) for minutes at 4CC. Sterilization of the clarified-saliva is done I I at 4°C with stirring by irradiation of the sample with UV light for 1.0 hour.
Each sintered disk is hydrated with sterile water in a polyethylene test tube. The water is then removed and replaced with 2.00 ml of saliva. A salivary pellicle is formed by incubating the disk overnight at 37°C with continuous shaking in a ,ater bath. After this treatment, the saliva is removed and the disks are treated with 1.00 ml of a solution containing Santibacterial agent (Triclosan) dentifrice liquid phase solution and incubated at 37 0 C with continuous shaking in the water bath.
After 30 minutes, the disk is transferred into a new tube and Io 5.00 ml of water L,,e added, followed by shaking the disk gently with a Vortex. The disk is then transferred into a new tube and the washing procedu'r repeated twice. Finally, the disk is transferred carefully into a new tube to avoid co-transfer of any liquid along with the disk. Then 1.00 ml of methanol is added to the disk and shaken vigorously with a Vortex. The sample is left at room temperature for 30 minutes to extract adsorbed Triclosan into the methanol. The methanol is then aspirated and clarified by centrifugation in a Beckman Microfuge 11 at 10,000 rpm to 5 minutes. After this treatment, the 0p O methanol is transferred into HPLC (high performance liquid chromatography) vials for determination of antibacterial agent.
0 Triplicate samples are used in all experiments.
.o For the test of retention of antibacterial agent to a oj e saliva coated HA disk, a saliva coated HA disk is treated with oo. dentifrice slurries as described above. After incubation or minues at 37°C, the HA disk is removed from the dentifrice slurry, washed twice with water, and then reincubated with 0oe *parafilm stimulated human whole saliva which had been clarified by centrifugation. After incubation at 37°C with constant shaking for various periods, the HA disk is removed from the saliva, and the amount of antibacterial agent (Triclosan) retained onto the disk and released into saliva is determined by analytical method using HPLC.
o a SFor the assay of delivery of antibacterial agent to buccal epithelial cells, the delivery is measured in order to determine the effect of PVM/MA on the delivery of antibacterial ?I 86 39 agent (Triclosan) to soft oral tissue from a dentifrice product. Buccal epithelial cells are collected with a wooden applicator stick by gently rubbing the oral mucosa. The cells are suspended in Resting Saliva Salts (Rss) Buffer (50 nM NaCI, 1.1 nM CaC1 2 and 0.6 nM
KH
2 P0 4 pH 7.0) to 5-6x105 cells/mi using a hemocytometer to enumerate the cells and kept in ice until use. 0.5 ml of cell suspension, preincubated to 37 C in a waterbath, is added with 0.5 ml of the test antibacterial agent solution and incubated at 37 0 C. The antibacterial agent solution in the incubation mixture is diluted at least 10 times in order to lower the surfactant concentration and prevent destruction of cell membranes by the surfactant. After 30 minutes of incubation, the cells are harvested by centrifugation in Beckman Microfuge 11 at 5,000 rpm for 5 minutes. The cells, collected as the pellet, are washed 3 times with RSS buffer and treated with 1.5 ml of methanol. The sample is mixed vigorously and is analyzed for antibacterial agent by the HPLC method.
N-I Dentifrices are prepared having the following formulas: Parts Propylene Glycol (1,2) Iota Carrageenan Gantrez S-97 T'icanium Dioxide Surbitol (70%) 1O sodium Fluoride Sodium saccharin Silica Thickener(Sylodent 15) Silica Polishing Agent (Zeodent 113) Triclosan Sodium Lauryl Sulfate Flavor oil A B 10.00 10.00 0.75 0.75 2.00 0.50 0.50 30.00 30.00 0.332 0.332 0.40 0.40 3.00 3.00 20.00 0.20 2.00 0.95 i. 00 100.00 Q.S. to 20.*00 0.20 2.*00 0.95 1.00 100.00 Ethyl Alcohol Water Q. S. to 4 94 44 04 4 04 4A The uptake of triclosan on the saliva coated hydroxyapatite disk and on buccal epithelial cells with and without the polymeric polycarboxylate, Gantrez S-97, is set forth in Table 1 below: TABLE 1 Uptake of Triclosan In Micrograms in micrograms x 105 Buccal Dentifrice On Saliva Coated Disk Epithelial Cells A 25.0 38.0 !0 B 54.0 96.0 These results reveal that the Gantrez material 'present in Dentifrice B) greatly enhances the delivery and uptake of triclosan to saliva coated hydroxyapatite disk and to the exfoliated buccal epithelial cells.
Similar results are obtained when the dentifrices contain 0.30 parts of triclosan.
EXAMPLE 4 In tests with saliva coated hydroxyapatite disks and exfoliated buccal epithelial cells different from those set 3 0-A forth in Example k\above, said dentifrice B containing 2.00% 4* Gantrez S-97 and 0.20% of triclosan, 10.00% of propylene glycol and 2.00% of sodium lauryl sulfate and an equivalently o 4. formulated Dentifrice ,cept for the presence of 0.30% of S, triclosan were compared witn a commercially available Dentifrice containing hydrated alumina polishing agent and 0.2% of triclosan, no Gantrez material, no propylene glycol, (d) zinc citrate, 2.5% of surface active agents sodium monofluorophosphate and hydrated alumina polishing agent; and 4 II 0 0 1 /2 the dentifrice formulation below which is similar to commercial Dentifrice C except for the presence of 0.30% of triclosan: DENTIFRICE C' Sorbitol 27.00 Scdium Carboxymethyl Cellulose 0.80 Sodium Monofluorophosphate 0.85 Zinc Citrate 0.50 Sodium Saccharin 0.18 Water 16.47 Hydrated Alumina Polishing Agent 50.00 Ethanol 0.20 Sodium Lauryl Sulfate 1.875 Sodium Dodecyl Benzene Sulfonate 0.625 Triclosan 0.30 Flavor 1.20 Since Dentifrices C and C' contain a total of 2.50% of surface active agent, more surface active agent is available to O dissolve triclosan than in Dentifrices B and B' which contain Sa d 0 2.00%. However, propylene glycol present in siliceous polishing C s agent Dentifrices 3 and B' (but not in hydrated alumina o a e polishing agent Dentifrices C and insures optimum dissolution of triclosan.
The advantage of Dentifrices B and B' (containing propylene glycol and Gantrez) over Dentifrices C and C' in C C
I
triclosan uptake on saliva coated hydroxyapatite disks and on exfoliated buccal epithelial cells is shown in the Table 2 below: TABLE 2 Delivery of Triclosan To Saliva Coated To Buccal Epithelial Hydroxyapatite Disk ells (in micrograms) in micrograms Epithelial Cell 41.1 101.6 77.4 142.0 20.4 61.0 42.6 100.0 Dentifrice B
B'
C
C'
Additional experiments with Dentifrice B' (0.3% Triclosan; Gantrez; Propylene Glycol) in a 50% slurry of the dentifrice to determine the retention of triclosan on the saliva coated hydroxyapatite disk ocer a period of time reveals retention of excellent levels of triclosan as shown in Table 3 below: TABLE 3 Retention of Triclosan Adsorption from Dentifrice Slurry a o b@D a, e 0 D 40 a94L o o.& *9*4l
*J
a 0 *~4 Time (in Minutes) 0 Retention of Triclosan (Micrograms/Disk) 97 t if .r c- These results indicate that dentifrices containing triclosan, Gantrez material and propylene glycol can provide enhanced delivery of triclosan to, and retention on, tooth surfaces and soft surfaces in the oral cavity, thereby providing improved antiplaque and antibacterial effects.
EXAMPLE For purpose of comparison formulas a and b below are prepared: Dentifrice \0 a b Glycerin 10.00 Propylene Glycol 10.00 Iota Carrageenan 0.60 0.60 Sorbitol 25.00 25.00 Sodium Saccharin 0.40 0.40 Sodium Fluoride 0.243 0.243 Titanium Dioxide 0.50 0.50 Gantrez S-97 2.00 2.00 Water 29.157 29.157 o it* O NaOH(50%) 2.00 2.00 u Zeodent 113 (Silica Polishing Agent) 20.00 20.00 0\ Sylodent 15 (Silica Thickener) 5.50 5.50 Flavor 1.10 1.10 Triclosan 0.50 0.50 SSodium Lauryl Sulfate 2.00 2.00 Ethanol 1.00 1.00 t 4 Sl c ~L Formula a is a dentifrice containing a Gantrez polycarboxylate, with 0.5% triclosan as an antibacterial antiplaque agent and no solubilizing agent. In Formula b, propylene glycol solubilizing agent is present.
Formula a is poor in delivery of triclosan on buccal epithelial cells while Formula b is markedly effective.
The foregoing results reveal excellent delivery of Triclosan dentifrice.
EXAMPLE 6 An "in-house" study was conducted on a group of iO volunteers to assess the effects of particular dentifrices in influencing plaque regrowth in accordance with the method described by Addy, Wills and Moran, J. Clin. Perio, 1983, Vol.
Pages 89-99. The dentifrices tested included a placebo control containing no triclosan and a dentifrice in aceordance with this invention containing 0.3% of triclosan, propylene glycol (instead of 3% polyethylene glycol 600) and 2% of Gantrez S-97 and humectant of propylene glycol and sorbitol The formulas of the dentifrices ar as follows: 00 0 0O00 00 o 0 *I0 0 0 Parts (ii) Placebo Invention Polyethylene Glycol. 600 Glycerine Propylene Glycol Sorbitol (70%) Sodium CArboxyinethyl Cellulose Iota Carrageenan Sodium BEnzoate Sodium Saccharin Sodium Fluoride Silica Polishing Agent (Zeodent 113) Silica Thickener (Sylox 15) Water Gantrez S-97 Triclosan Titanium Dioxide -b sodium Lauryl Sulfate Flavor Ethyl Alcohol Sodium Hydroxide (50%) 3.00 25.00 41.617 0.35 0.50 0.20 0,*243 18.00 5.50 1.00 0.50 1.20 0.89 10.00 25.00 0 0.40 0.243 20.00 5.50 28.757 2.00 0.30 0.50 2.50 1.10 1.00 2.00 *040 O 0 0 00 0 0 00 00 0 0000 00 0 0 0 000 O 00 O 0 0 0060 0000 0000 47 With regard to plaque reduction, on the teeth of the volunteers, compared to placebo invention (ii) provided a significant decrease of Since lesser amounts of propylene glycol can dissolve P 5 the 0.3% of triclosan present in Toothpaste similar results are expected when the amount of propylene glycol is reduced to 0.5 parts and the amount of sorbitol is increased to 39.5 parts. Likewise, the other solubilizing agents dipropylene glycol, hexylene glycol, methyl cellosolve, ethyl cellosolve, olive oil, castor oil, petrolatum, amyl acetate, glyceryl tristearate and benzyl benzoate, in place of propylene glycol, can effectively deliver triclosan to soft oral tissues. Further, similar results are expected when propylene glycol or other solubilizing agents are omitted from toothpaste (ii) containing 0.3% triclosan.
i EXAMPLE 7 The following dentifrices of the invention are prepared: Parts A B Glycerine 20.00 Propylene Glycol 10.00 0.50 Sorbitol 25.00 19.50 Sodium Carboxymethyl Cellulose 1.10 Iota Carrageenan 0.600 Sodium Saccharin 0.40 0.30 Sodium Fluoride 0.243 0.243 Silica Polishing (Zeodent 113) 20.00 20.00 Silica thickener (Sylox 15) 5.50 3.00 Water 28.757 15.307 Gantrez S-97 2.00 2.00 Triclosan 0.50 0.30 Titanium Dioxide 0.50 0.50 b Sodium Lauryl Sulfate 2.50 2.00 a Flavor 1.10 0.95 Ethanol 1.00 Sodium Hydroxide 2.00 1.60 0 004 In the foregoing examples, improved results may also be obtained by replacing triclosan with other antibacterial agents herein described such as phenol, thymol, eugenol and 2,2'methylene bis (4-chloro-6-bromophenol) and/or by replacing Gantrez with other AEA's such as a 1:1 copolymer of maleic i' anhydride and ethyl acrylate, sulfoacrylic oligomers, Carbopols 0 934), polymers of monomeric alpha- or beta-styrene phosphonic acid and copolymers of these styrene phosphonic acid monomers with each other or with other ethylenically unsaturated polymerizable monomers such as vinyl phosphonic acid.
i r e l r Example 8 The following dentifrice is prepared: Alpha Alumina Trihydrate Propylene Glycol Sorbitol (70%) Gantrez S-97 (13% solution) Gantrez S-97 (powder) Sodium Lauryl Sulfate Sodium Saccharine Sodium Hyroxide (50%) Flavor Irish Moss Sodium carboxymethyl celluose Sodium monofluorophosphate Titanium Dioxide Triclosan Water 48.00 21.70 15.00 2.00 0.30 1.20 0.95 1.00 0.76 0.30 Q.S. to 100.00 Parts
B
48.00 0.50 21.70 15.00 2.13 0.30 1.20 0,95 1.00 0.76 0.50 0.30
Q.S.
100.00
C
48.00 0.50 21.70 2.00 2.13 0.30 1.20 0.95 1.00 0.76 0.50 0.30 to Q.S. to 100.00 0 0 0 00 0 0o o 0 00 0,0 0 0 l00 The foregoing dentifrices deliver triclosan to the teeth and soft tissue areas of the gums substantially more effectively than corresponding dentifrices in which the Gantrez polycarboxylate is absent.
il EXAMPLE 9 The following dentifrices are prepared: Parts Glycerine Sorbitol (70%) Sodium Carboxymethyl cellulose Gantrez S-97 Sodium Saccharin Sodium Benzoate sodium Monofluorophsophate Dicalcium Phosphate Dihydrate Triclosan Sodium Lauryl sulfate 22.00 1.00 2.00 0.20 0.50 0.76 48.76 0.30 1.20 0.89 to 100.00 10.00 17.00 1.00 2.00 0.20 0.50 0.76 48.76 0.30 1.20 0 .89 Q.S. to 100.00 Flavor Watcr QS Q. S.
The f oregoing dentif rices coated IA:. 1 disk corresponding dentifrices polycarboxylate is absent.
deliver triclosan to saliva more effectively than in which the Gantrez 04*0 o 0 0 40 0 o 04 00 0 0000 o 0 o 0~@0 0 04 0 0 0000 0440 EXAMPLE The following antiplaque dentifrice is prepared: Parts Glycerine 15.00 Propylene Glycol 2.00 Sodium Carboxymethyl cellulose 1.50 Water 24.93 Vinyl Methyl Ether/Maleic Anhydride copolymer 4.76 jo (42% solution) Sodium Monofluorophosphate 0.76 Sodium Saccharin 0.30 Insoluble Sodium Metaphosphate 47.00 Titanium Dioxide 0.50 Sodium Lauryl Sulfate 2.00 Triclosan 0.30 Flavor 0.95 In the foregoing examples improved results are also achievable when triclosan is replaced with each of phenol, 2,2'-methylene bis (4-chloro-6-Bromophenol), eugenol and thymol, and/or when Gantrez is replaced by other AEA's such as Carbopols 934) or styrene phosphonic acid polymers having molecular weights within the range of about 0, 3,000 to 10,000 such as poly (beta-styrenephosphonic acid), copolymers of vinyl phosphonic acid with betastyrenephosphonic acid, and poly (alpha-styrenephosphonic Sacid), or sulfoacrylic oligomers, or a 1:1 copolymer of 0* maleic anhydride with ethyl acrylate.
0 o «Jg P o r c" i EXAMPLE 11 Dentifrice Mobile Phases Containing Triclosan Components Composition, A B Sorbitol 53.33 40.00 Water 40.48 39.15 Santrez S 13.33 NaOH 1.33 Saccharin 0.40 0.40 o0 Sodium Fluoride 0.32 0.32 Flavor Oil 1.47 1.47 Sodium Lauryl Sulfate 3.33 3.33 Triclosan 0.67 0.67 The concentration of the above components are 1.33% dentifrice level to reflect 25% level of abrasive which may e needed to make a complete dentifrice.
The above mobile phases of the indicated dentifrice formulations are tested for triclosan uptake on saliva coated HA disks. Results are in the Table below: o a 04 O 0« 52 0 0 6P i- r i i
TABLE
Uptake of Triclosan by Saliva Coated Hydroxyapatite (HA) Disks from Diluted and Undiluted Dentifrice Mobile Phases.
Triclosan Ionic Strength (calculated) pH Triclosan Uptake (ug/disk) Undiluted
A
0.67 0.375 8.7 55
B
0.67 7.6 122 The above results show a greater then two fold increase in triclosan uptake achieved with the B formulation containing Gantrez relative to the A formulation without the Gantrez.
EXAMPLE 12 Concentration and Uptake of Triclosan by HA 1:1 Dentifrice/Water Slurries.
Dentifrice Containing Triclosan (ug/ml) in Triclosan, 2.5% Supernatant of 1:1 sodium Lauryl Slurry Sulfate from
T
'p Hydrated silica 1,650 Gantrez S-97 Alumina Gantrez S-97 1,905 Supernatants of 1:1 Dentifrice/Water s above dentifrices are tested for concentration o: in the supernatant and for triclosan uptake on s disks. The results indicate that using 50% a.
increases the triclosan substantially under lo conditions (from 1,650 to 1,905), resulting in increase in the triclosan uptake (from 52 to 74).
Supernatant of riclosan Uptake g/disk 52 74 lurries of the f the triclosan aliva coated HA Lumina abrasive w i:1)dilution a substantial 99 L ~Afv 77" E EXAMPLE 13 The mouthrinses below are effective in reducing plaque by increasing the uptake and retention of triclosan oral surfaces.
Gantrez S-97 Glycerine Ethanol I) Propylono Glycol Pluronic F108- (Polyoxyethylone/Polyoxypropylone Block Copolymeor) Sodium Lauryl Sulfate Triclosan Flavoring Oil
QS.
Water1
A
Parts 0.24 15.00
D
Parts 0.25 10.00 C D Parts Parts 0.25 0.25 15.00 10.00 1t2.50 12.50 5.00 5.00 2.00
-E
Parts 0.25 15.00 0.20 0.03 0.40 Q. S. to 100.00 0.10 0.10 0.40 0.40 to QS. to 00.00 100.00 0.20 0.*06 0.40 Q. S. to 100.00 0.20 0.06 0.40 Q. S. to 100,00 44 o 0 09 0 9 40 0 0 9 06 o 4 00 wj 7,
S
EXAMPLE 14 The f ollowing liquid dentif rices are also ef fective in reducing plaque by increasing the uptake and retenti on of triclosan on oral surf a z: Glycerine Gantrez S-97 Polysaccharide of high molecular weight, the molecule containing mannose, glucose, potassium glucuronate and acetyl moieties in the approximate molar ratio of 2:1:1:1 Sodium benzoate saccharine sodium Water Sod.ium lauryl sulfate insoluble sodium metal phc ate Anhydrous dicalcium phiosphate Flavoring Oil Ethyl alcohol Triclosan
A
Parts 20.0 0.3 0.Z 0.5 0.5 61.3 3.0 10.0 1.0 2.5 0.1
B
Parts 20.. 0 0.3
C
Parts 0.3 0.5 0 .5 73.1 71.6 3.0Q 10.0 2.5 10.0 0.1 0.1 0400 0 00 00 0 0 44 04 S 0404 04 0 0 404 04 00 4 0444 0044 0 0040 0I I I~ 44 1 4 4.4 In the forq-.1ng Examples, improved results are also achievable when triclosan is z-eplaced with each of phenol, 2,2'methylene bis (4-chloro-G-Bromophenol), euagenol and thymol, and/or when Gantrez is replaced by other ABA's such as Carbopols 934) or styrene phosphonic acid polymers having molecular weights within the range of about 3,000 to 10,000 such as poly 3) (beta- styrenephosphonic acid), copolymers of vinyl phosphonic acid with beta- styrenephosphonic, acid, and poly (alpha- ,tyrenephosphonic acid), or z%:i.foa,-;rylic oligomers, or a 1-1 copolymer of maleic anhydride th ethyl acrylate.
This Invention~ Aas boon described with .'spect to certain preferred erriidiments and It will be understood that modifications and variations thereof obvious to those sk,U.led in the art are to be included witri~in ehe purview of this application and the scope of the appended claims.
40 4 00 0 40 4 000404 0 0 04 ~4 4t I 4 I 401401 O 1

Claims (34)

1. An oral composition comprising an effective antiplaque amount of a substantially water insoluble noncationic antibacterial agent, 0.005-4% by weight of antibacterial enhancing agent which enhances delivery of said antibacterial agent to, and retention on, oral surfaces by attaching or substantively, adhesively, cohesively or otherwise bonding the antibacterial enhancing agent to oral surfaces, and an orally acceptable vehicle effective to enable said antibacterial agent to dissolve in saliva in effective antiplaque amount, said oral composition being substantially free of polyphosphate anticalculus agent.
2. The oral composition claimed in claim 1, wherein said oral composition is a dentifrice comprising 5-30% by weight of a siliceous polishing agent and said antibacterial agent is present in amount of 0.25-0.35% by weight and there is present at least one of a surface-active agent and a flavoring oil.
3. The oral composition claimed in claim 1, wherein said oral composition is a dentifrice comprising 5-30% by weight of a siliceous polishing agent, said antibacterial agent is present in amount of 0.01-5% by weight and said oral composition comprises a solubilizing material in amount sufficient to dissolve said antibacterial agent in saliva.
4. The Oral composition claimed in claim 3, wherein said antibacterial agent is present in amount of 0.05% up to below 0.25% by weight.
5. The oral composition claimed in claim 3, wherein said antibacterial agent is present -in amount of above 0.35% up to 5% by weight.
6. The oral composition claimed in claim 5, wherein said antibacterial agent is present in amount of above 0.35% up 1 to 0.5% by weight. L 1. i i i 57
7. The oral composition claimed in claim 1, wherein said oral composition is a dentifrice comprising 30-75% by weight of a dentally acceptable water-insoluble polishing agent.
8. The oral composition claimed in claim 1, wherein said oral composition is a mouthwash or liquid dentifrice and said orally acceptable vehicle is an aqueous vehicle wherein there is present at least one a surface-active agent, a flavoring oil or a non-toxic alcohol.
9. The oral composition dentifrice according to any of the preceding claims wherein there is present surface-active agent in amount of 0.5-5% by weight. The oral composition dentifrice claimed in any of the preceding claims wherein there is present flavoring oil in amount of 0.1-5% by weight.
11. The oral composition claimed in claim 8 wherein said composition is a mouthwash and said aqueous vehicle contains ethanol and the weight ratio of water to ethanol is from 1:1 to 20:1.
12. The oral composition claimed in claim 8 wherein said oral composition is a liquid dentifrice containing 0.3-2.0% by weight of a polysaccharide of high molecular weight in excess of 1,000,000 containing mannose, glucose, potassium gluctronate and acetyl moieties in the approximate ratio of 2:1:1:1, as suspending and thickening agent and 10-20% by weight of a polishing material.
13. The oral composition claimed in any of claim 1-8 whereir said antibacterial agent is selected from the group consisting of halogenated diphenyl ethers, halogenated salicylanilides, benzoic esters, halofenated carbanilides and phenolic compounds.
14. The oral composition claimed in claim 13 wherein said antibacterial agent is a halogenated diphenyl eter. The oral composition claimed in claim 14 wherein said halogenated diphenyl ether is 2,4,4'-trichloro-2'-hydroxyphenyl I i 58 ether.
16. The oral composition dentifrice according to any one of claims 1 and 3-6 wherein a solubilizing agent is present in amount of 0.5 to 50% by weight and is selected from the group consisting of propylene glycol, dipropylene glycol, hexylene glycol, methyl cellosolve, ethyl cellosolve, vegetable oil and wax containing at least 12 carbon atoms, amyl acetate, ethyl acetate, glyceryl tristearate and benzyl benzoate.
17. The oral composition dentifrice claimed in claim 16 wherein a solubilizing agent is propylene glycol and is present in amount of 0.5% by weight.
18. The oral composition claimed in either of claims 1 or 16 wherein a polishing agent is present which is selected from the group consisting of sodium metaphosphate, tricalcium phosphate, dihydrated dicalcium phosphate, anhydrous dicalcium phosphate, calcium pyrophosphate, magnesium orthophosphate, trimagnesium phosphate, calcium carbonate, aluminium silicate, hydrated alumina, silica, bentonite and mixtures hereof and said oral composition is a dentifrice.
19. The oral composition dentifrice claimed in claim 18 wherein said polishing agent is dicalcium phosphate dihydrate or hydrated alumina.
20. The oral composition according to any of claims 1-8 wherein said antibacterial-enhancing agent has an average moleculao weight of 100 to 1,000,000.
21. The orail composition according to claim 20 claims wherein said antibacterial-enhancing agent contains at least one delivery-enhancing functional group and at least one organic retention-enhancing group.
22. The oral composition according to claim 21 wherein said delivery-enhancing group is acidic. 59
23. The oral composition according to claim 22 wherein said delivery-enhancing group is selected from the group consisting of carboxylic, phosphonic, phosphinic, and sulfonic acids, and their salts, and mixtures thereof.
24. The oral composition according to claim 23 wherein said organic retention-enhancing group comprises the formula O(X)n-R wherein X is 0, N, S, SO, S02, P, PO or Si, R is hydrophobic alkyl, alkylene, acyl, aryl, alkaryl aralkyl, heterocyclic, or their inert-substituted derivatives, and n is 1 or zero. The oral composition according to any of claims 20-24 wherein said antibacterial-enhancing agent is an anionic polymer containing a plurality of said delivery-enhancing and retention-enhancing groups.
26. The oral composition according to claim 25 wherein said anionic polymer comprises a chain containing repeating units each containing at least one carbon atom.
27. The oral composition according to claim 26 wherein each unit contains at least one delivery-enhancing group bonded to the same, vicinal, or other atoms in the chain.
28. The oral composition according to claim 23 wherein the delivery-enhancing group is a carboxylic group of salt thereof.
29. The oral composition according to claim 28 wherein the antibacterial-enhancing agent is a copolymer of maleic acid or anhydride with another inert ethylenically Sunsaturated polymerizable monomer. The oral composition according to claim 29 wherein said other monomer of said copolymer is methyl vinyl ether in a 4:1 to 1:4 molar ratio with the maleic acid or anhydride.
31. The oral composition according to claim 30 wherein said copolymer has a molecular weight of 30,000-1,000,000 and is present in amount of 0.1-2% by weight. S, U _t 60
32. A compcoition according to claim 31 wherein the copolymer has an average molecular weight of about 70,000.
33. A composition according to claim 23 wherein the delivery-enhancing group is a phosphonic group or salt thereof.
34. A composition according to claim 33 wherein the antibacterial-enhancing agent is poly (beta-styrenephosphonic acid) or poly (alpha-styrenephosphonic acid) polymer or a copolymer of either styrenephosphonic acid with another ethylenically unsaturated monomer. A method of controlling oral plaque comprising applying to oral surfaces an effective plaque-controlling amount of a composition as defined in any of the preceding claims.
36. An oral composition comprising an orally acceptable vehicle, an effective antiplaque amount of a substantially water insoluble noncationic antibacterial agent and an antibacterial-enhancing agent which has an average molecular weight of 1,000 to 1,000,000, contains at least one delivery enhancing functional group which attaches or substantively, adhesively or cohesively or otherwise bonds the antibacterial enhancing agent to oral surfaces, and at least one organic retention enhancing group, said agent containing said groups being free from or substantially free from water soluble alkali metal or ammonium synthetic anionic linear polymer polycarboxylate salt having a molecular weight of 1,000 to 1,000,000.
37. The oral preparation claimed in claim 36 wherein said antibacterial agent is present in amount of from 0.25% to less than 0.5% by weight.
38. The oral preparation claimed in claim 36 wherein said antibacterial agent is present in amount of from 0.25% to 0.35% by weight.
61- 39. The oral preparation claimed in claim 37 wherein said oral composition contains a siliceous polishing agent. The oral preparation claimed in claim 38 wherein said oral composition contains a siliceous polishing agent. DATED this 16 day of March 1992 COLGATE-PALMOLIVE COMPANY Patent Attorneys for the Applicant: F B. RICE CO. i
AU46769/89A 1988-12-29 1989-12-13 Antiplaque antibacterial oral composition Expired AU625379B2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US07/291,712 US4894220A (en) 1987-01-30 1988-12-29 Antibacterial antiplaque oral composition
US39860689A 1989-08-25 1989-08-25
US39860589A 1989-08-25 1989-08-25
US39966989A 1989-08-25 1989-08-25
US07/398,566 US5032386A (en) 1988-12-29 1989-08-25 Antiplaque antibacterial oral composition
US07/398,592 US5188821A (en) 1987-01-30 1989-08-25 Antibacterial antiplaque oral composition mouthwash or liquid dentifrice
US41068289A 1989-09-21 1989-09-21
US291712 1989-09-21
US398566 1989-09-21
US399669 1989-09-21
US410682 1989-09-21
US398606 1989-09-21
US398605 1989-09-21
US398592 1989-09-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU24519/92A Division AU654874B2 (en) 1988-12-29 1992-09-15 Antiplaque antibacterial oral composition

Publications (2)

Publication Number Publication Date
AU4676989A AU4676989A (en) 1990-07-05
AU625379B2 true AU625379B2 (en) 1992-07-09

Family

ID=27569612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46769/89A Expired AU625379B2 (en) 1988-12-29 1989-12-13 Antiplaque antibacterial oral composition

Country Status (31)

Country Link
JP (1) JP2708134B2 (en)
CN (1) CN1048867C (en)
AT (1) AT397765B (en)
AU (1) AU625379B2 (en)
BR (1) BR8906866A (en)
CH (1) CH679639A5 (en)
DE (1) DE3942643B4 (en)
DK (1) DK175071B1 (en)
DZ (2) DZ1382A1 (en)
FI (1) FI100691B (en)
FR (2) FR2641186B1 (en)
GB (3) GB2227660B (en)
GR (1) GR1004463B (en)
HK (3) HK154796A (en)
HU (1) HU212183B (en)
IE (1) IE65326B1 (en)
IL (1) IL92692A0 (en)
IT (1) IT1237483B (en)
LU (1) LU87650A1 (en)
MA (1) MA21712A1 (en)
MX (1) MX173741B (en)
MY (1) MY105879A (en)
NL (1) NL194716C (en)
NO (1) NO179503C (en)
NZ (1) NZ231813A (en)
OA (1) OA09253A (en)
PL (1) PL165470B1 (en)
PT (1) PT92734B (en)
SE (2) SE507731C2 (en)
SK (1) SK280567B6 (en)
ZW (1) ZW17289A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256401A (en) * 1987-01-30 1993-10-26 Colgate-Palmolive Company Antibacterial antiplaque mouthwash composition
US5334375A (en) * 1988-12-29 1994-08-02 Colgate Palmolive Company Antibacterial antiplaque oral composition
SE512333C2 (en) * 1989-08-25 2000-02-28 Colgate Palmolive Co Antibacterial oral composition with plaque- and tartar-limiting action
IL92693A0 (en) * 1989-08-25 1990-09-17 Colgate Palmolive Co Antibacterial antiplaque composition containing novel styrene-phosphonic acid copolymer
AU9179791A (en) * 1990-12-19 1992-07-22 Procter & Gamble Company, The Oral compositions effective against plaque and gingivitis
US5094844A (en) * 1990-12-20 1992-03-10 Colgate-Palmolive Company Anticalculus oral composition
US5385729A (en) * 1991-08-01 1995-01-31 Colgate Palmolive Company Viscoelastic personal care composition
US5252313A (en) * 1991-12-20 1993-10-12 Colgate-Palmolive Company Visually clear gel dentifrice
US5192533A (en) * 1992-03-25 1993-03-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Nonirritating antitartar and antiplaque oral compositions
NZ247712A (en) * 1992-06-19 1995-04-27 Colgate Palmolive Co Oral composition comprising an anti-bacterial compound, a water-insoluble biodegradable polymer, and an organic solvent
WO1995017879A1 (en) * 1993-12-29 1995-07-06 The Procter & Gamble Company Tartar control dentifrice composition containing thymol
US5462728A (en) * 1994-04-05 1995-10-31 Blank; Izhak Pharmaceutical compositions
JP3494739B2 (en) * 1995-02-13 2004-02-09 株式会社ジーシー Tooth surface treatment agent for dental glass ionomer cement
HUP0100090A3 (en) * 1997-12-18 2002-11-28 Unilever Nv Oral care composition
KR100384103B1 (en) * 1998-04-02 2003-10-08 주식회사 태평양 An oral composition containing triclosan
US6241972B1 (en) * 1999-02-19 2001-06-05 Block Drug Company, Inc. Oral care formulation for the treatment of sensitivity teeth
DE10051955A1 (en) * 2000-10-20 2002-05-02 Wella Ag Hair treatment agent in the form of a solid and dimensionally stable gel
AU2002216059A1 (en) 2000-12-15 2002-06-24 Joiner, Andrew Oral bleaching composition
RU2278709C2 (en) 2001-01-16 2006-06-27 Унилевер Н.В. Peroral composition
WO2003006519A1 (en) * 2001-07-13 2003-01-23 Kao Corporation Polymers for oral use and compositions for oral use
US6912826B2 (en) 2002-10-07 2005-07-05 Zoran Momich Carrier loading cartoner
US7846422B2 (en) 2003-08-04 2010-12-07 Kao Corporation Method for prevention or treatment of periodontal diseases and composition for an oral cavity
US20060024245A1 (en) * 2004-07-29 2006-02-02 Cadbury Adams, Llc. Tooth whitening compositions and delivery systems therefor
US8974772B2 (en) 2004-12-28 2015-03-10 Colgate-Palmolive Company Two phase toothpaste composition
EP3100716B1 (en) * 2008-02-08 2018-09-26 Colgate-Palmolive Company Novel salts and their uses
CN102368996A (en) * 2009-04-02 2012-03-07 高露洁-棕榄公司 Dentifrice composition
WO2011020684A2 (en) 2009-08-19 2011-02-24 Unilever Plc Delivery system
WO2011109919A1 (en) 2010-03-09 2011-09-15 Unilever Plc Stable oral care compositions
BR112013002226A2 (en) * 2010-07-29 2016-05-24 Colgate Palmolive Co phosphate-free oral care compositions based on magnolia antibacterial agent
CN107308010A (en) 2010-09-10 2017-11-03 荷兰联合利华有限公司 Composite particles active matter and its manufacture method
EP2613756B1 (en) 2010-09-10 2017-08-02 Unilever PLC, a company registered in England and Wales under company no. 41424 Oral care compositions for benefiting teeth
EP2699217B1 (en) 2011-04-18 2018-01-24 Unilever N.V. Tooth remineralizing oral care compositions
EP3302350B1 (en) 2015-06-05 2022-07-20 Unilever IP Holdings B.V. Method of whitening teeth
EA035371B1 (en) 2015-06-05 2020-06-03 Юнилевер Н.В. Enamel regeneration system
US20180125625A1 (en) 2015-06-05 2018-05-10 Conopco, Inc., D/B/A Unilever Oral care device
EP3222326A1 (en) 2016-03-23 2017-09-27 Unilever PLC Toothpaste composition
EP3295921A1 (en) 2016-09-14 2018-03-21 Unilever PLC Use of oral care composition
GB201811065D0 (en) * 2018-07-05 2018-08-22 GlaxoSmithKline Consumer Healthcare UK IP Ltd Novel composition
EP3849507A1 (en) 2018-09-12 2021-07-21 Unilever Global Ip Limited Oral care composition
WO2020212159A1 (en) 2019-04-17 2020-10-22 Unilever Plc Oral care product
EP3888621A1 (en) 2020-04-02 2021-10-06 Unilever Global IP Ltd Oral care device
EP3888622A1 (en) 2020-04-02 2021-10-06 Unilever Global IP Ltd Oral care system
EP3888620A1 (en) 2020-04-02 2021-10-06 Unilever Global IP Ltd Oral care system
EP3888619A1 (en) 2020-04-02 2021-10-06 Unilever Global IP Ltd Oral care device
EP3888623A1 (en) 2020-04-02 2021-10-06 Unilever Global IP Ltd Oral care system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7461887A (en) * 1986-06-25 1988-01-07 Beecham Group Plc Oral hygiene composition containing an antibacterial agent
AU4676889A (en) * 1988-12-29 1990-07-05 Colgate-Palmolive Company, The Packaged anti-plaque oral compositions
AU4676689A (en) * 1989-08-25 1991-02-28 Colgate-Palmolive Company, The Antibacterial antiplaque, anticalculus oral composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429963A (en) * 1964-06-09 1969-02-25 Colgate Palmolive Co Dental preparation containing polymeric polyelectrolyte
US3629477A (en) * 1966-08-08 1971-12-21 Geigy Chem Corp Halogenated diphenyether-containing compositions and control of pests therewith
ZA717486B (en) * 1970-11-19 1973-06-27 Colgate Palmolive Co Treatment of teeth
US3897548A (en) * 1973-04-09 1975-07-29 Indiana University Foundation Oral compositions for retarding the formation of dental plaque and methods of utilization thereof
US4022880A (en) * 1973-09-26 1977-05-10 Lever Brothers Company Anticalculus composition
US4138477A (en) * 1976-05-28 1979-02-06 Colgate Palmolive Company Composition to control mouth odor
US4342857A (en) * 1980-12-31 1982-08-03 Colgate-Palmolive Company Antigingivitis composition comprising vinyl phosphonic acid/vinyl phosphonyl fluoride copolymer
JPS5988416A (en) * 1982-11-15 1984-05-22 ジヨンソン・エンド・ジヨンソン・プロダクツ・インコ−ポレ−テツド Oral sanitary composition
DE3445695A1 (en) * 1983-12-28 1985-07-11 Colgate-Palmolive Co., New York, N.Y. AGENT FOR ORAL-DENTAL APPLICATION AGAINST PLAQUE AND GINGIVITIS
GB8411841D0 (en) * 1984-05-09 1984-06-13 Unilever Plc Oral compositions
GB8526093D0 (en) * 1985-10-22 1985-11-27 Beecham Group Plc Composition
JPH0772125B2 (en) * 1986-08-29 1995-08-02 ライオン株式会社 Oral composition
IN168400B (en) * 1987-01-30 1991-03-23 Colgate Palmolive Co

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7461887A (en) * 1986-06-25 1988-01-07 Beecham Group Plc Oral hygiene composition containing an antibacterial agent
AU4676889A (en) * 1988-12-29 1990-07-05 Colgate-Palmolive Company, The Packaged anti-plaque oral compositions
AU4676689A (en) * 1989-08-25 1991-02-28 Colgate-Palmolive Company, The Antibacterial antiplaque, anticalculus oral composition

Also Published As

Publication number Publication date
ATA296889A (en) 1993-11-15
SK751289A3 (en) 2000-03-13
DZ1699A1 (en) 2002-02-17
DK670989D0 (en) 1989-12-28
IT8948694A0 (en) 1989-12-22
NO179503B (en) 1996-07-15
NZ231813A (en) 1992-05-26
DE3942643B4 (en) 2008-03-27
GR1004463B (en) 2004-02-27
CN1048867C (en) 2000-02-02
HU896808D0 (en) 1990-03-28
MY105879A (en) 1995-02-28
PT92734A (en) 1990-06-29
NO179503C (en) 1996-10-23
FI896316A0 (en) 1989-12-28
DK175071B1 (en) 2004-05-24
SE9703681L (en) 1997-10-09
GB2257362B (en) 1993-09-01
GB9216778D0 (en) 1992-09-23
NL194716C (en) 2003-01-07
FR2681529A1 (en) 1993-03-26
SE9703681D0 (en) 1997-10-09
GB2259856A (en) 1993-03-31
MX173741B (en) 1994-03-25
NO895310D0 (en) 1989-12-28
NL8903187A (en) 1990-07-16
HK154996A (en) 1996-08-23
IT1237483B (en) 1993-06-07
HK154796A (en) 1996-08-23
JPH02288819A (en) 1990-11-28
SE507731C2 (en) 1998-07-06
NO895310L (en) 1990-07-02
NL194716B (en) 2002-09-02
SE8904180L (en) 1990-06-30
CN1044047A (en) 1990-07-25
GB2227660A (en) 1990-08-08
PT92734B (en) 1996-06-28
AU4676989A (en) 1990-07-05
HU212183B (en) 1996-03-28
FR2681529B1 (en) 1994-07-22
IL92692A0 (en) 1990-09-17
FR2641186A1 (en) 1990-07-06
IE894195L (en) 1990-06-29
CH679639A5 (en) 1992-03-31
IE65326B1 (en) 1995-10-18
MA21712A1 (en) 1990-07-01
DE3942643A1 (en) 1990-07-05
GB9225278D0 (en) 1993-01-27
AT397765B (en) 1994-06-27
SE8904180D0 (en) 1989-12-12
GB2259856B (en) 1993-09-01
BR8906866A (en) 1990-10-09
SE510832C2 (en) 1999-06-28
SK280567B6 (en) 2000-03-13
GB8928878D0 (en) 1990-02-28
PL283117A1 (en) 1991-02-11
GB2257362A (en) 1993-01-13
GR890100853A (en) 1991-03-15
DK670989A (en) 1990-06-30
GB2227660B (en) 1993-09-01
DZ1382A1 (en) 2004-09-13
OA09253A (en) 1992-06-30
ZW17289A1 (en) 1992-01-01
LU87650A1 (en) 1990-07-10
HK154896A (en) 1996-08-23
FR2641186B1 (en) 1994-12-23
PL165470B1 (en) 1994-12-30
FI100691B (en) 1998-02-13
JP2708134B2 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
AU625379B2 (en) Antiplaque antibacterial oral composition
US5538715A (en) Antibacterial antiplaque oral composition
AU654874B2 (en) Antiplaque antibacterial oral composition
US5180578A (en) Antibacterial antiplaque anticalculus oral composition
US5192531A (en) Antibacterial antiplaque oral composition
US5032386A (en) Antiplaque antibacterial oral composition
US5288480A (en) Antiplaque antibacterial oral composition
US5188821A (en) Antibacterial antiplaque oral composition mouthwash or liquid dentifrice
AU640355B2 (en) Antibacterial antiplaque, anticalculus oral composition
US5294431A (en) Antibacterial antiplaque oral composition mouthwash or liquid dentifrice
GB2200551A (en) Antibacterial antiplaque, anticalculus oral composition
US5192530A (en) Antibacterial antiplaque oral composition
US5178851A (en) Antiplaque antibacterial oral composition
US5453265A (en) Antibacterial antiplaque oral composition
US5312618A (en) Antibacterial antiplaque oral composition
CA2006717C (en) Antibacterial anti-plaque oral composition mouthwash or liquid dentifrice
CA2006716C (en) Antibacterial antiplaque oral composition
IE914419A1 (en) Methods for making oral compositions
IE65678B1 (en) Antiplaque antibacterial oral composition